223 related articles for article (PubMed ID: 1772782)
1. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
[TBL] [Abstract][Full Text] [Related]
2. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
[TBL] [Abstract][Full Text] [Related]
3. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
Hampton KK; Preston FE; Lowe GD; Walker ID; Sampson B
Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
[TBL] [Abstract][Full Text] [Related]
4. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
[TBL] [Abstract][Full Text] [Related]
5. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
[TBL] [Abstract][Full Text] [Related]
6. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience of a new monoclonal antibody purified factor IX: half-life, recovery, and safety in patients with hemophilia B.
Kim HC; McMillan CW; White GC; Bergman GE; Saidi P
Semin Hematol; 1990 Apr; 27(2 Suppl 2):30-5. PubMed ID: 2094957
[TBL] [Abstract][Full Text] [Related]
8. Purified factor IX using monoclonal immunoaffinity technique: clinical trials in hemophilia B and comparison to prothrombin complex concentrates.
Kim HC; McMillan CW; White GC; Bergman GE; Horton MW; Saidi P
Blood; 1992 Feb; 79(3):568-75. PubMed ID: 1531035
[TBL] [Abstract][Full Text] [Related]
9. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
[TBL] [Abstract][Full Text] [Related]
10. Factor IXa-factor VIIIa-cell surface complex does not contribute to the basal activation of the coagulation mechanism in vivo.
Bauer KA; Mannucci PM; Gringeri A; Tradati F; Barzegar S; Kass BL; ten Cate H; Kestin AS; Brettler DB; Rosenberg RD
Blood; 1992 Apr; 79(8):2039-47. PubMed ID: 1562731
[TBL] [Abstract][Full Text] [Related]
11. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
13. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
[TBL] [Abstract][Full Text] [Related]
14. Factor IX from prothrombin complex concentrate augments low dose tissue factor-triggered thrombin generation in vitro.
Hasan S; Abuelkasem E; Williams B; Henderson R; Mazzeffi MA; Tanaka KA
Br J Anaesth; 2018 Oct; 121(4):936-943. PubMed ID: 30236256
[TBL] [Abstract][Full Text] [Related]
15. Human coagulation factor IX: assessment of thrombogenicity in animal models and viral safety.
Herring SW; Abildgaard C; Shitanishi KT; Harrison J; Gendler S; Heldebrant CM
J Lab Clin Med; 1993 Mar; 121(3):394-405. PubMed ID: 8445288
[TBL] [Abstract][Full Text] [Related]
16. Increased thrombin generation in a child with a combined factor IX and protein C deficiency.
Negrier C; Berruyer M; Durin A; Philippe N; Dechavanne M
Blood; 1993 Feb; 81(3):690-5. PubMed ID: 8427961
[TBL] [Abstract][Full Text] [Related]
17. Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitors.
Abildgaard CF; Britton M; Harrison J
J Pediatr; 1976 Feb; 88(2):200-5. PubMed ID: 1249680
[TBL] [Abstract][Full Text] [Related]
18. Thrombotic safety of prothrombin complex concentrate (Beriplex P/N) for dabigatran reversal in a rabbit model.
Herzog E; Kaspereit FJ; Krege W; Doerr B; van Ryn J; Dickneite G; Pragst I
Thromb Res; 2014 Sep; 134(3):729-36. PubMed ID: 25084749
[TBL] [Abstract][Full Text] [Related]
19. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy.
Ohga S; Saito M; Matsukazi A; Kai T; Ueda K
Br J Haematol; 1993 Jun; 84(2):343-5. PubMed ID: 8398841
[TBL] [Abstract][Full Text] [Related]
20. An investigation of three patients with Christmas disease due to an abnormal type of factor IX.
Denson KW; Biggs R; Mannucci PM
J Clin Pathol; 1968 Mar; 21(2):160-5. PubMed ID: 4972271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
